Highlighted Text:
Show |
Hide
Full text loading...
Chapter 13 : Diagnosis of Viral Infections*
Authors:
Guy Boivin,
Tony Mazzulli,
Martin Petric,
Michel Couillard
Content Type: Reference
Publication Year:
2009
Category: Viruses and Viral Pathogenesis
Book DOI:
10.1128/9781555815981
Chapter DOI:
10.1128/9781555815981.ch13
MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Preview this chapter:
Diagnosis of Viral Infections*, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap13-1.gif /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap13-2.gif
Abstract:
The traditional epidemiological and academic reasons for diagnosis of viral infections have been expanded by rapid, often quantitative assays that can impact on therapeutic management and public health decisions. All methods used for viral isolation require living cells because viruses are obligate intracellular parasites. Historically, the systems used to isolate viruses of medical importance consisted of laboratory animals, embryonated eggs, and cultured cells. In the past two decades, safe and effective antiviral drugs have been developed for the treatment of many acute and chronic viral infections. In most diagnostic laboratories, electron microscopy (EM) for the diagnosis of viral infections has been supplanted by other methods, but EM remains an important and often rapid method for detecting viruses in clinical samples. Viral serologic assays contribute significantly to the indirect diagnosis of acute, recent, or chronic viral infections and are used widely for determining the immune status of a person or group of individuals with regard to a specific virus or to verify the immune response to vaccination. A variety of methods are available for serodiagnosis of viral infections. Failure to establish an accurate serologic diagnosis frequently results from the inability to submit an adequate pair of serum samples.
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
Key Concept Ranking
- Severe Acute Respiratory Syndrome
- 0.44596973
- Upper Respiratory Tract Infections
- 0.428145
- West nile virus
- 0.41415444
- Sin nombre virus
- 0.4131443
0.44596973
Figures
Diagnosis of Viral Infections*
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815981.ch13-1,webId=/content/author/10.1128/9781555815981.ch13-1,properties={foaf_givenname=Guy, foaf_name=Guy Boivin, foaf_surname=Boivin}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815981.ch13-2,webId=/content/author/10.1128/9781555815981.ch13-2,properties={foaf_givenname=Tony, foaf_name=Tony Mazzulli, foaf_surname=Mazzulli}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815981.ch13-3,webId=/content/author/10.1128/9781555815981.ch13-3,properties={foaf_givenname=Martin, foaf_name=Martin Petric, foaf_surname=Petric}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815981.ch13-4,webId=/content/author/10.1128/9781555815981.ch13-4,properties={foaf_givenname=Michel, foaf_name=Michel Couillard, foaf_surname=Couillard}]]
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13fig01
FIGURE 1
CPE induced by some viruses. Row A shows uninfected cell lines, including HEp-2 cells (
1
), RD cells (
2
), fibroblasts (
3
), and Vero cells (
4
). Row B shows the same cell lines infected with RSV (
1
), enterovirus (
2
), CMV (
3
), and HSV (
4
).
10.1128/9781555815981/f0268-01_thmb.gif
10.1128/9781555815981/f0268-01.gif
FIGURE 1
CPE induced by some viruses. Row A shows uninfected cell lines, including HEp-2 cells ( 1 ), RD cells ( 2 ), fibroblasts ( 3 ), and Vero cells ( 4 ). Row B shows the same cell lines infected with RSV ( 1 ), enterovirus ( 2 ), CMV ( 3 ), and HSV ( 4 ).
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13fig02
FIGURE 2
CMV UL97 mutations associated with ganciclovir resistance. CMV UL97 conserved regions are represented by shaded boxes. Numbers under the boxes indicate the positions (codon numbers) of these conserved regions. Vertical bars indicate the presence of amino acid substitutions, while the hatched box indicates a region (codons 590 to 607) in which diverse deletions (from 1 to 17 codons) have been reported.
10.1128/9781555815981/f0270-01_thmb.gif
10.1128/9781555815981/f0270-01.gif
FIGURE 2
CMV UL97 mutations associated with ganciclovir resistance. CMV UL97 conserved regions are represented by shaded boxes. Numbers under the boxes indicate the positions (codon numbers) of these conserved regions. Vertical bars indicate the presence of amino acid substitutions, while the hatched box indicates a region (codons 590 to 607) in which diverse deletions (from 1 to 17 codons) have been reported.
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13fig03
FIGURE 3
PCR. The strands of the target DNA are separated by heating (melting), and on cooling they anneal with the complementary primers present in excess. The thermostable DNA polymerase extends the primers, forming two double-stranded DNA molecules. On subsequent heating, the strands separate and each anneals with the complementary primer. The cycling of temperature among melting, annealing, and primer extension is repeated multiple times, and the number of product strands is doubled with each cycle. (Reprinted from reference
141a
with permission.)
10.1128/9781555815981/f0275-01_thmb.gif
10.1128/9781555815981/f0275-01.gif
FIGURE 3
PCR. The strands of the target DNA are separated by heating (melting), and on cooling they anneal with the complementary primers present in excess. The thermostable DNA polymerase extends the primers, forming two double-stranded DNA molecules. On subsequent heating, the strands separate and each anneals with the complementary primer. The cycling of temperature among melting, annealing, and primer extension is repeated multiple times, and the number of product strands is doubled with each cycle. (Reprinted from reference 141a with permission.)
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13fig04
FIGURE 4
RVP assay (Luminex Molecular Diagnostics Inc.). Identification of the target-specific primer extension (TSPE) reaction that has been captured on the microbead is achieved through the oligonucleotide tag. Sorting of the microbeads occurs in the Luminex 100 flow cell instrument, which identifies colored beads with one laser and a phycoerythrin signal on the attached extended amplicon with a second laser.
10.1128/9781555815981/f0276-01_thmb.gif
10.1128/9781555815981/f0276-01.gif
FIGURE 4
RVP assay (Luminex Molecular Diagnostics Inc.). Identification of the target-specific primer extension (TSPE) reaction that has been captured on the microbead is achieved through the oligonucleotide tag. Sorting of the microbeads occurs in the Luminex 100 flow cell instrument, which identifies colored beads with one laser and a phycoerythrin signal on the attached extended amplicon with a second laser.
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13fig05
FIGURE 5
Real-time PCR (TaqMan process). In this thermocycling reaction, the internal probe, which is conjugated to the fluorescent dye (F) and the quencher dye (Q), hybridizes with the denatured target DNA. When these two dyes are present in close proximity on the probe, the fluorescence of the F dye is quenched. When the new strand being synthesized as an extension of the terminal primers reaches the probe, it is digested by the 5′ exonuclease activity of the thermostable polymerase, liberating the F dye and resulting in the generation of a fluorescent signal. (Reprinted from reference
141a
with permission.)
10.1128/9781555815981/f0276-02_thmb.gif
10.1128/9781555815981/f0276-02.gif
FIGURE 5
Real-time PCR (TaqMan process). In this thermocycling reaction, the internal probe, which is conjugated to the fluorescent dye (F) and the quencher dye (Q), hybridizes with the denatured target DNA. When these two dyes are present in close proximity on the probe, the fluorescence of the F dye is quenched. When the new strand being synthesized as an extension of the terminal primers reaches the probe, it is digested by the 5′ exonuclease activity of the thermostable polymerase, liberating the F dye and resulting in the generation of a fluorescent signal. (Reprinted from reference 141a with permission.)
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13fig06
FIGURE 6
Strand displacement amplification. This isothermal amplification assay is based on four requirements, namely, primers which include an upstream restriction endonuclease site (BsoB1), the cognate enzyme (BsoB1), a DNA polymerase lacking 5′ exonuclease activity, and nucleoside triphosphates, of which one has been modified to contain an alpha-thiol group (dCTPαS). In this reaction, the target DNA anneals with the primers and is converted to a double-stranded form by the polymerase. The restriction endonuclease introduces a cleavage in the primer sequence, and the polymerase synthesizes a new strand from this site and displaces the existing strand. The restriction endonuclease is not able to cut the newly synthesized strands because of the modified nucleotides and can only introduce cuts in the sites present in the primers. Restriction site-bearing primers are designed to anneal to sequences of both strands of the target DNA, resulting in an exponential synthesis of displaced strands. (Adapted from reference
141a
with permission.)
10.1128/9781555815981/f0277-01_thmb.gif
10.1128/9781555815981/f0277-01.gif
FIGURE 6
Strand displacement amplification. This isothermal amplification assay is based on four requirements, namely, primers which include an upstream restriction endonuclease site (BsoB1), the cognate enzyme (BsoB1), a DNA polymerase lacking 5′ exonuclease activity, and nucleoside triphosphates, of which one has been modified to contain an alpha-thiol group (dCTPαS). In this reaction, the target DNA anneals with the primers and is converted to a double-stranded form by the polymerase. The restriction endonuclease introduces a cleavage in the primer sequence, and the polymerase synthesizes a new strand from this site and displaces the existing strand. The restriction endonuclease is not able to cut the newly synthesized strands because of the modified nucleotides and can only introduce cuts in the sites present in the primers. Restriction site-bearing primers are designed to anneal to sequences of both strands of the target DNA, resulting in an exponential synthesis of displaced strands. (Adapted from reference 141a with permission.)
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13fig07
FIGURE 7
Ligase chain reaction. This reaction includes two pairs of primers, each pair annealing to one strand of heat-denatured target DNA with a gap of 2 to 7 nucleotides between. The primers are designed to bind so that the gap between them consists of a single nucleotide type. The reaction also contains the relevant nucleotide triphosphates, a thermostable DNA polymerase, and a thermostable DNA ligase. Once the gap is filled by the polymerase, the ligase joins the last nucleotide to the downstream primer. The temperature is then raised to denature the product and then lowered to allow further primer binding. The cycle is repeated so that additional primer pairs can be ligated. By having the upstream primer labeled at the 5′ end with biotin (B) and the downstream primer labeled at the 3′ end with a fluorescent label, the products can be captured on a solid phase and tested for the presence of the fluorescent label. (Reprinted from reference
141a
with permission.)
10.1128/9781555815981/f0277-02_thmb.gif
10.1128/9781555815981/f0277-02.gif
FIGURE 7
Ligase chain reaction. This reaction includes two pairs of primers, each pair annealing to one strand of heat-denatured target DNA with a gap of 2 to 7 nucleotides between. The primers are designed to bind so that the gap between them consists of a single nucleotide type. The reaction also contains the relevant nucleotide triphosphates, a thermostable DNA polymerase, and a thermostable DNA ligase. Once the gap is filled by the polymerase, the ligase joins the last nucleotide to the downstream primer. The temperature is then raised to denature the product and then lowered to allow further primer binding. The cycle is repeated so that additional primer pairs can be ligated. By having the upstream primer labeled at the 5′ end with biotin (B) and the downstream primer labeled at the 3′ end with a fluorescent label, the products can be captured on a solid phase and tested for the presence of the fluorescent label. (Reprinted from reference 141a with permission.)
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13fig08
FIGURE 8
NASBA. This procedure is particularly well adapted to the detection of RNA. The reaction mixture consists of one primer which contains the sequence for the T7 RNA polymerase promoter at its 5′ end, a second primer at the downstream end of the sequence to be amplified, T7 RNA polymerase, reverse transcriptase, and RNase H as well as the ribo- and deoxyribonucleotide triphosphates. When the primer containing the T7 promoter anneals to the target RNA, the reverse transcriptase synthesizes the complementary DNA strand and the RNA portion of this duplex is digested by the RNase H. After binding of the downstream primer, the reverse transcriptase synthesizes a double-stranded DNA with a T7 promoter at one end which serves as a template for the T7 RNA polymerase, which synthesizes approximately 1,000 copies of antisense RNA in a promoter-dependent manner. This RNA can be further reverse transcribed to double-stranded DNA which can serve as a template on which the RNA polymerase can synthesize multiple antisense RNA copies. (Reprinted from reference
141a
with permission.)
10.1128/9781555815981/f0278-01_thmb.gif
10.1128/9781555815981/f0278-01.gif
FIGURE 8
NASBA. This procedure is particularly well adapted to the detection of RNA. The reaction mixture consists of one primer which contains the sequence for the T7 RNA polymerase promoter at its 5′ end, a second primer at the downstream end of the sequence to be amplified, T7 RNA polymerase, reverse transcriptase, and RNase H as well as the ribo- and deoxyribonucleotide triphosphates. When the primer containing the T7 promoter anneals to the target RNA, the reverse transcriptase synthesizes the complementary DNA strand and the RNA portion of this duplex is digested by the RNase H. After binding of the downstream primer, the reverse transcriptase synthesizes a double-stranded DNA with a T7 promoter at one end which serves as a template for the T7 RNA polymerase, which synthesizes approximately 1,000 copies of antisense RNA in a promoter-dependent manner. This RNA can be further reverse transcribed to double-stranded DNA which can serve as a template on which the RNA polymerase can synthesize multiple antisense RNA copies. (Reprinted from reference 141a with permission.)
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13fig09
FIGURE 9
Branched-chain DNA (bDNA) assay of first (A) and third (B) generations. Target DNA hybridizes to capture probes linked to a solid phase. A short oligonucleotide called the label extender hybridizes with complementary sequences on the target DNA and with either the amplifier oligonucleotide shown in panel A or a longer oligonucleotide called the preamplifier that contains multiple repeat sequences, shown in panel B. Amplifier oligonucleotides then hybridize to the alkaline phosphatase-linked probes shown in panel A as well as the preamplifier sites shown in panel B. Alkaline phosphatase is detected by standard reagents for the enzyme.
10.1128/9781555815981/f0279-01_thmb.gif
10.1128/9781555815981/f0279-01.gif
FIGURE 9
Branched-chain DNA (bDNA) assay of first (A) and third (B) generations. Target DNA hybridizes to capture probes linked to a solid phase. A short oligonucleotide called the label extender hybridizes with complementary sequences on the target DNA and with either the amplifier oligonucleotide shown in panel A or a longer oligonucleotide called the preamplifier that contains multiple repeat sequences, shown in panel B. Amplifier oligonucleotides then hybridize to the alkaline phosphatase-linked probes shown in panel A as well as the preamplifier sites shown in panel B. Alkaline phosphatase is detected by standard reagents for the enzyme.
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13fig10
FIGURE 10
Diagram depicting the typical IgM and IgG antibody responses following primary viral infection, reactivation, or reinfection. During primary infection, IgM appears within several days after onset of symptoms, peaks at 7 to 10 days, and normally declines to undetectable levels within 1 to 3 months. Following natural viral infection or successful immunization, IgG antibodies appear several days after the production of IgM, reach higher levels than IgM, and can persist for years, even lifelong, in lower quantities. During reactivation or exogenous reinfection, an anamnestic response in IgG antibodies will occur and an IgM response may or may not be observed.
10.1128/9781555815981/f0282-01_thmb.gif
10.1128/9781555815981/f0282-01.gif
FIGURE 10
Diagram depicting the typical IgM and IgG antibody responses following primary viral infection, reactivation, or reinfection. During primary infection, IgM appears within several days after onset of symptoms, peaks at 7 to 10 days, and normally declines to undetectable levels within 1 to 3 months. Following natural viral infection or successful immunization, IgG antibodies appear several days after the production of IgM, reach higher levels than IgM, and can persist for years, even lifelong, in lower quantities. During reactivation or exogenous reinfection, an anamnestic response in IgG antibodies will occur and an IgM response may or may not be observed.
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
References
/content/book/10.1128/9781555815981.ch13
1.
Abed, Y.,, A. M. Bourgault,, R. J. Fenton,, P. J. Morley,, D. Gower,, I. J. Owens,, M. Tisdale, and, G. Boivin. 2002. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J. Infect. Dis. 186: 1074– 1080.
2.
Abed, Y.,, I. Hardy,, Y. Li, and, G. Boivin. 2002. Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada. J. Med. Virol. 67: 589– 595.
3.
Allander, T.,, M. T. Tammi,, M. Eriksson,, A. Bjerkner,, A. Tiveljung-Lindell, and, B. Andersson. 2005. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl. Acad. Sci. USA 102: 12891– 12896.
4.
Andiman, W. A. 1991. Organism-specific antibody indices, the cerebrospinal fluid-immunoglobulin index and other tools: a clinician’s guide to the etiologic diagnosis of central nervous system infection. Pediatr. Infect. Dis. J. 10: 490– 495.
5.
Arens, M. Q.,, and E. M. Swierkosz. 2007. Susceptibility test methods: viruses, p. 1705–1718. In P. R. Murray,, E. J. Baron,, J. H. Jorgensen,, M. L. Landry, and, M. A. Pfaller (ed.), Manual of Clinical Microbiology, 9th ed. ASM Press, Washington, DC.
6.
Ballew, H. C. 2000. Neutralization, p. 127–134. In S. C. Specter,, R. L. Hodinka, and, S. A. Young (ed.), Clinical Virology Manual, 3rd ed. ASM Press, Washington, DC.
7.
Baz, M.,, Y. Abed,, J. McDonald, and, G. Boivin. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin. Infect. Dis. 43: 1555– 1561.
8.
Bellisario, R.,, R. J. Colinas, and, K. A. Pass. 2001. Simultaneous measurement of antibodies to three HIV-1 antigens in newborn dried blood-spot specimens using a multiplexed microsphere-based immunoassay. Early. Hum. Dev. 64: 21– 25.
9.
Belshe, R. B.,, B. Burk,, F. Newman,, R. L. Cerruti, and, I. S. Sim. 1989. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J. Infect. Dis. 159: 430– 435.
10.
Bettoli, E. J.,, P. M. Brewer,, M. J. Oxtoby,, A. A. Zaidi, and, M. E. Guinan. 1982. The role of temperature and swab materials in the recovery of herpes simplex virus from lesions. J. Infect. Dis. 145: 399.
11.
Biel, S. S.,, and H. R. Gelderblom. 1999. Diagnostic electron microscopy is still a timely and rewarding method. J. Clin. Virol. 13: 105– 119.
12.
Biggar, R. J.,, W. Miley,, P. Miotti,, T. E. Taha,, A. Butcher,, J. Spadoro, and, D. Waters. 1997. Blood collection on filter paper: a practical approach to sample collection for studies of perinatal HIV transmission. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14: 368– 373.
13.
Blackburn, N. K.,, T. G. Besselaar,, B. D. Schoub, and, K. F. O’Connell. 1991. Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity. J. Med. Virol. 33: 6– 9.
14.
Boivin, G.,, S. Chou,, M. R. Quirk,, A. Erice, and, M. C. Jordan. 1996. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J. Infect. Dis. 173: 523– 528.
15.
Boivin, G.,, C. K. Edelman,, L. Pedneault,, C. L. Talarico,, K. K. Biron, and, H. H. Balfour, Jr. 1994. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J. Infect. Dis. 170: 68– 75.
16.
Boivin, G.,, C. Gilbert,, A. Gaudreau,, I. Greenfield,, R. Sudlow, and, N. A. Roberts. 2001. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Infect. Dis. 184: 1598– 1602.
17.
Boivin, G.,, N. Goyette,, C. Gilbert,, A. Humar, and, E. Covington. 2005. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transplant Infect. Dis. 7: 166– 170.
18.
Boucher, C. A.,, W. Keulen,, T. van Bommel,, M. Nijhuis,, D. de Jong,, M. D. de Jong,, P. Schipper, and, N. K. Back. 1996. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob. Agents Chemother. 40: 2404– 2409.
19.
Brown, M.,, M. Petric, and, P. J. Middleton. 1984. Silver staining of DNA restriction fragments for the rapid identification of adenovirus isolates: application during nosocomial outbreaks. J. Virol. Methods 9: 87– 98.
20.
Cane, P. A.,, P. Cook,, D. Ratcliffe,, D. Mutimer, and, D. Pillay. 1999. Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob. Agents Chemother. 43: 1600– 1608.
21.
Carpenter, A. B. 2007. Immunoassays for the diagnosis of infectious diseases, p. 257–270. In P. R. Murray,, E. J. Baron,, M. A. Pfaller,, F. C. Tenover, and, R. H. Yolken (ed.), Manual of Clinical Microbiology, 9th ed. ASM Press, Washington, DC.
22.
Chan, P. K.,, W. K. To,, K. C. Ng,, R. K. Lam,, T. K. Ng,, R. C. Chan,, A. Wu,, W. C. Yu,, N. Lee,, D. S. Hui,, S. T. Lai,, E. K. Hon,, C. K. Li,, J. J. Sung, and, J. S. Tam. 2004. Laboratory diagnosis of SARS. Emerg. Infect. Dis. 10: 825– 831.
23.
Chou, S.,, S. Guentzel,, K. R. Michels,, R. C. Miner, and, W. L. Drew. 1995. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 172: 239– 242.
24.
Chou, S.,, N. S. Lurain,, K. D. Thompson,, R. C. Miner, and, W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188: 32– 39.
25.
Condorelli, F.,, G. Scalia,, A. Stivala,, R. Gallo,, A. Marino,, C. M. Battaglini, and, A. Castro. 1994. Detection of immunoglobulin G to measles virus, rubella virus, and mumps virus in serum samples and in microquantities of whole blood dried on filter paper. J. Virol. Methods 49: 25– 36.
26.
Constantine, N. T.,, R. Saville, and, E. Dax. 2005. Retroviral Testing and Quality Assurance: Essentials for Laboratory Diagnosis. Malloy Printers.
27.
Curry, A.,, H. Appleton, and, B. Dowsett. 2006. Application of transmission electron microscopy to the clinical study of viral and bacterial infections: present and future. Micron 37: 91– 106.
28.
Dankner, W. M.,, D. Scholl,, S. C. Stanat,, M. Martin,, R. L. Sonke, and, S. A. Spector. 1990. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J. Virol. Methods 28: 293– 298.
29.
de Mezerville, M. H.,, R. Tellier,, S. Richardson,, D. Hebert,, J. Doyle, and, U. Allen. 2006. Adenoviral infections in pediatric transplant recipients: a hospital-based study. Pediatr. Infect. Dis. J. 25: 815– 818.
30.
Drachenberg, C. B.,, H. H. Hirsch,, E. Ramos, and, J. C. Papadimitriou. 2005. Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods. Hum. Pathol. 36: 1245– 1255.
31.
Drosten, C.,, S. Gunther,, W. Preiser,, S. van der Werf,, H. R. Brodt,, S. Becker,, H. Rabenau,, M. Panning,, L. Kolesnikova,, R. A. Fouchier,, A. Berger,, A. M. Burguiere,, J. Cinatl,, M. Eickmann,, N. Escriou,, K. Grywna,, S. Kramme,, J. C. Manuguerra,, S. Muller,, V. Rickerts,, M. Sturmer,, S. Vieth,, H. D. Klenk,, A. D. Osterhaus,, H. Schmitz, and, H. W. Doerr. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348: 1967– 1976.
32.
Dunn, D. T.,, C. D. Brandt,, A. Krivine,, S. A. Cassol,, P. Roques,, W. Borkowsky,, A. De Rossi,, E. Denamur,, A. Ehrnst, and, C. Loveday. 1995. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intrapartum transmission. AIDS 9: F7– 11.
33.
Dunn, J. J.,, R. D. Woolstenhulme,, J. Langer, and, K. C. Carroll. 2004. Sensitivity of respiratory virus culture when screening with R-Mix fresh cells. J. Clin. Microbiol. 42: 79– 82.
34.
Dybul, M.,, A. S. Fauci,, J. G. Bartlett,, J. E. Kaplan, and, A. K. Pau. 2002. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. Morb. Mortal. Wkly. Rep. Recomm. Rep. 51: 1– 55.
35.
Enders, J. F.,, T. H. Weller, and, F. C. Robbins. 1949. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109: 85– 87.
36.
Erdman, D. D. 2000. Immunoglobulin M determinations, p. 146–153. In S. C. Specter,, R. L. Hodinka, and, S. A. Young (ed.), Clinical Virology Manual, 3rd ed. ASM Press, Washington, DC.
37.
Erice, A.,, S. Chou,, K. K. Biron,, S. C. Stanat,, H. H. Balfour, Jr., and, M. C. Jordan. 1989. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320: 289– 293.
38.
Espy, M. J.,, J. R. Uhl,, P. S. Mitchell,, J. N. Thorvilson,, K. A. Svien,, A. D. Wold, and, T. F. Smith. 2000. Diagnosis of herpes simplex virus infections in the clinical laboratory by LightCycler PCR. J. Clin. Microbiol. 38: 795– 799.
39.
Fahy, E.,, D. Y. Kwoh, and, T. R. Gingeras. 1991. Self-sustained sequence replication (3SR): an isothermal transcription-based amplification system alternative to PCR. PCR Methods Appl. 1: 25– 33.
40.
Feld, J. J.,, and J. H. Hoofnagle. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967– 972.
41.
Feller, A. E.,, J. F. Enders, and, T. H. Weller. 1940. The prolonged coexistence of vaccinia virus in high titre and living cells in roller tube cultures of chick embryonic tissues. J. Exp. Med. 72: 367– 388.
42.
Forman, M. S.,, and A. Valsamakis. 2007. Specimen collection, transport, and processing: virology, p. 1284–1296. In P. R. Murray,, E. J. Baron,, J. H. Jorgensen,, M. L. Landry, and, M. A. Pfaller (ed.), Manual of Clinical Microbiology, 9th ed. ASM Press, Washington, DC.
43.
Fulton, R. J.,, R. L. McDade,, P. L. Smith,, L. J. Kienker, and, J. R. Kettman, Jr. 1997. Advanced multiplexed analysis with the FlowMetrix system. Clin. Chem. 43: 1749– 1756.
44.
Gey, G. O. 1933. An improved technique for massive tissue culture. Am. J. Cancer 17: 752– 756.
45.
Gilbert, C.,, and G. Boivin. 2003. Discordant phenotypes and genotypes of cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. AIDS 17: 337– 341.
46.
Gilbert, C.,, J. Handfield,, E. Toma,, R. Lalonde,, M. G. Bergeron, and, G. Boivin. 1998. Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS 12: 125– 129.
47.
Gleaves, C. A.,, T. F. Smith,, E. A. Shuster, and, G. R. Pearson. 1984. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J. Clin. Microbiol. 19: 917– 919.
48.
Gottfried, T. D.,, J. C. Sturge, and, H. B. Urnovitz. 1999. A urine test system for HIV-1 antibodies. Am. Clin. Lab. 18: 4.
49.
Gray, R. H.,, M. J. Wawer,, R. Brookmeyer,, N. K. Sewankambo,, D. Serwadda,, F. Wabwire-Mangen,, T. Lutalo,, X. Li,, T. vanCott, and, T. C. Quinn. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357: 1149– 1153.
50.
Guatelli, J. C.,, K. M. Whitfield,, D. Y. Kwoh,, K. J. Barringer,, D. D. Richman, and, T. R. Gingeras. 1990. Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. Proc. Natl. Acad. Sci. USA 87: 1874– 1878.
51.
Gürtler, L.,, A. Mühlbacher,, U. Michl,, H. Hofmann,, G. G. Paggi,, V. Bossi,, R. Thorstensson,, R. G. Villaescusa,, A. Eiras,, J. M. Hernandez,, W. Melchior,, F. Donie, and, B. Weber. 1998. Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. J. Virol. Methods 75: 27– 38.
52.
Gutfreund, K. S.,, M. Williams,, R. George,, V. G. Bain,, M. M. Ma,, E. M. Yoshida,, J. P. Villeneuve,, K. P. Fischer, and, D. L. Tyrrel. 2000. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J. Hepatol. 33: 469– 475.
53.
Hanna, G. J.,, V. A. Johnson,, D. R. Kuritzkes,, D. D. Richman,, J. Martinez-Picado,, L. Sutton,, J. D. Hazel-wood, and, R. T. D’Aquila. 2000. Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase. J. Clin. Microbiol. 38: 2715– 2721.
54.
Hayden, F.,, A. Klimov,, M. Tashiro,, A. Hay,, A. Monto,, J. McKimm-Breschkin,, C. Macken,, A. Hampson,, R. G. Webster,, M. Amyard, and, M. Zambon. 2005. Neuraminidase Inhibitor Susceptibility Network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir. Ther. 10: 873– 877.
55.
Hazelton, P. R.,, and H. R. Gelderblom. 2003. Electron microscopy for rapid diagnosis of infectious agents in emergent situations. Emerg. Infect. Dis. 9: 294– 303.
56.
Herrera, G. A.,, R. Veeramachaneni, and, E. A. Turbat-Herrera. 2005. Electron microscopy in the diagnosis of BK-polyoma virus infection in the transplanted kidney. Ultrastruct. Pathol. 29: 469– 474.
57.
Hirsch, M. S.,, F. Brun-Vezinet,, B. Clotet,, B. Conway,, D. R. Kuritzkes,, R. T. D’Aquila,, L. M. Demeter,, S. M. Hammer,, V. A. Johnson,, C. Loveday,, J. W. Mellors,, D. M. Jacobsen, and, D. D. Richman. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37: 113– 128.
58.
Hodinka, R. L. 1999. Serological tests in clinical virology, p. 195–211. In E. H. Lennette and, T. F. Smith (ed.), Laboratory Diagnosis of Viral Infections, 3rd ed. Marcel Dekker, Inc., New York, NY.
59.
Hodinka, R. L.,, T. Nagashunmugam, and, D. Malamud. 1998. Detection of human immunodeficiency virus antibodies in oral fluids. Clin. Diagn. Lab. Immunol. 5: 419– 426.
60.
Huang, Y. T.,, and B. M. Turchek. 2000. Mink lung cells and mixed mink lung and A549 cells for rapid detection of influenza virus and other respiratory viruses. J. Clin. Microbiol. 38: 422– 423.
61.
Hughes, M. D.,, V. A. Johnson,, M. S. Hirsch,, J. W. Bremer,, T. Elbeik,, A. Erice,, D. R. Kuritzkes,, W. A. Scott,, S. A. Spector,, N. Basgoz,, M. A. Fischl, and, R. T. D’Aquila for the ACTG 241 Protocol Virology Substudy Team. 1997. Monitoring plasma HIV-1 RNA levels in addition to CD4 + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann. Intern. Med. 126: 929– 938.
62.
Hurt, A. C.,, R. Alexander,, J. Hibbert,, N. Deed, and, I. G. Barr. 2007. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J. Clin. Virol. 39: 132– 135.
63.
Ison, M. G.,, L. V. Gubareva,, R. L. Atmar,, J. Treanor, and, F. G. Hayden. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193: 760– 764.
64.
Itoh, Y.,, M. Takahashi,, M. Fukuda,, T. Shibayama,, T. Ishikawa,, F. Tsuda,, T. Tanaka,, T. Nishizawa, and, H. Okamoto. 2000. Visualization of TT virus particles recovered from the sera and feces of infected humans. Biochem. Biophys. Res. Commun. 279: 718– 724.
65.
Jacob, S.,, D. Baudy,, E. Jones,, L. Xu,, A. Mason,, F. Regenstein, and, R. P. Perrillo. 1997. Comparison of quantitative HCV RNA assays in chronic hepatitis C. Am. J. Clin. Pathol. 107: 362– 367.
66.
Japour, A. J.,, D. L. Mayers,, V. A. Johnson,, D. R. Kuritzkes,, L. A. Beckett,, J. M. Arduino,, J. Lane,, R. J. Black,, P. S. Reichelderfer,, R. T. D’Aquila,, C. S. Crumpacker, the RV-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37: 1095– 1101.
67.
Jayashree, S.,, M. K. Bhan,, R. Kumar,, P. Raj,, R. Glass, and, N. Bhandari. 1988. Serum and salivary antibodies as indicators of rotavirus infection in neonates. J. Infect. Dis. 158: 1117– 1120.
68.
Johnson, G.,, S. Nelson,, M. Petric, and, R. Tellier. 2000. Comprehensive PCR-based assay for detection and species identification of human herpesviruses. J. Clin. Microbiol. 38: 3274– 3279.
69.
Jordens, J. Z.,, S. Lanham,, M. A. Pickett,, S. Amarasekara,, I. Abeywickrema, and, P. J. Watt. 2000. Amplification with molecular beacon primers and reverse line blotting for the detection and typing of human papillomaviruses. J. Virol. Methods 89: 29– 37.
70.
Kageyama, T.,, S. Kojima,, M. Shinohara,, K. Uchida,, S. Fukushi,, F. B. Hoshino,, N. Takeda, and, K. Katayama. 2003. Broadly reactive and highly sensitive assay for Norwalk-like viruses based on real-time quantitative reverse transcription-PCR. J. Clin. Microbiol. 41: 1548– 1557.
71.
Kasahara, Y. 1997. Agglutination immunoassays, p. 7–12. In N. R. Rose,, E. Conway de Macario,, J. D. Folds,, E. C. Lane, and, M. Nakamura (ed.), Manual of Clinical Laboratory Immunology, 5th ed. ASM Press, Washington, DC.
72.
Kaufman, E.,, and I. B. Lamster. 2002. The diagnostic applications of saliva—a review. Crit. Rev. Oral Biol. Med. 13: 197– 212.
73.
King, S. M.,, M. Petric,, R. Superina,, N. Graham, and, E. A. Roberts. 1990. Cytomegalovirus infections in pediatric liver transplantation. Am. J. Dis. Child. 144: 1307– 1310.
74.
Kiviat, N. B.,, L. A. Koutsky,, C. W. Critchlow,, D. A. Galloway,, D. A. Vernon,, M. L. Peterson,, P. E. McElhose,, S. J. Pendras,, C. E. Stevens, and, K. K. Holmes. 1990. Comparison of Southern transfer hybridization and dot filter hybridization for detection of cervical human papillomavirus infection with types 6, 11, 16, 18, 31, 33, and 35. Am. J. Clin. Pathol. 94: 561– 565.
75.
Klimov, A. I.,, E. Rocha,, F. G. Hayden,, P. A. Shult,, L. F. Roumillat, and, N. J. Cox. 1995. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J. Infect. Dis. 172: 1352– 1355.
76.
Klutts, J. S.,, R. S. Liao,, W. M. Dunne, Jr., and, A. M. Gronowski. 2004. Evaluation of a multiplexed bead assay for assessment of Epstein-Barr virus immunologic status. J. Clin. Microbiol. 42: 4996– 5000.
77.
Kostouros, E.,, K. Siu,, E. L. Ford-Jones,, M. Petric, and, R. Tellier. 2003. Molecular characterization of rotavirus strains from children in Toronto, Canada. J. Clin. Virol. 28: 77– 84.
78.
Kramski, M.,, H. Meisel,, B. Klempa,, D. H. Kruger,, G. Pauli, and, A. Nitsche. 2007. Detection and typing of human pathogenic hantaviruses by real-time reverse transcription-PCR and pyrosequencing. Clin. Chem. 53: 1899– 1905.
79.
Lai, Y.,, K. L. Feldman, and, R. S. Clark. 2005. Enzyme-linked immunosorbent assays (ELISAs). Crit. Care Med. 33: S433– S434.
80.
Landry, M. L.,, A. M. Caliendo,, Y. W. Tang, and, A. Valsamakis. 2007. Algorithms for detection and identification of viruses, p. 1304–1307. In P. R. Murray,, E. J. Baron,, J. H. Jorgensen,, M. L. Landry, and, M. A. Pfaller (ed.), Manual of Clinical Microbiology, 9th ed. ASM Press, Washington, DC.
81.
Landry, M. L.,, S. Stanat,, K. Biron,, D. Brambilla,, W. Britt,, J. Jokela,, S. Chou,, W. L. Drew,, A. Erice,, B. Gilliam,, N. Lurain,, J. Manischewitz,, R. Miner,, M. Nokta,, P. Reichelderfer,, S. Spector,, A. Weinberg,, B. Yen-Lieberman, and, C. Crumpacker. 2000. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 44: 688– 692.
82.
Laperche, S.,, N. Le Marrec,, A. Girault,, F. Bouchardeau,, A. Servant-Delmas,, M. Maniez-Montreuil,, P. Gallian,, T. Levayer,, P. Morel, and, N. Simon. 2005. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J. Clin. Microbiol. 43: 3877– 3883.
83.
Leary, J. J.,, R. Wittrock,, R. T. Sarisky,, A. Weinberg, and, M. J. Levin. 2002. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob. Agents Chemother. 46: 762– 768.
84.
Ledue, T. B.,, and D. E. Garfin. 1997. Immunofixation and immunoblotting, p. 54–64. In N. R. Rose,, E. Conway de Macario,, J. D. Folds,, E. C. Lane, and, R. M. Nakamura (ed.), Manual of Clinical Laboratory Immunology, 5th ed. ASM Press, Washington, DC.
85.
Leland, D. S. 1996. Concepts of immunoserological and molecular techniques, p. 21–49. In D. S. Leland (ed.), Clinical Virology. The W. B. Saunders Co., Philadelphia, PA.
86.
Lennette, E. T.,, D. J. Blackbourn, and, J. A. Levy. 1996. Antibodies to human herpesvirus type 8 in the general population and in Kaposi’s sarcoma patients. Lancet 348: 858– 861.
87.
Lennette, E. T.,, and D. A. Lennette. 2000. Immune adherence hemagglutination, p. 140–145. In S. C. Specter,, R. L. Hodinka, and, S. A. Young (ed.), Clinical Virology Manual, 3rd ed. ASM Press, Washington, DC.
88.
Levin, M. J.,, S. Leventhal, and, H. A. Masters. 1984. Factors influencing quantitative isolation of varicellazoster virus. J. Clin. Microbiol. 19: 880– 883.
89.
Limaye, A. P. 2002. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 35: 866– 872.
90.
Livak, K. J.,, S. J. Flood,, J. Marmaro,, W. Giusti, and, K. Deetz. 1995. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 4: 357– 362.
91.
Longo, M. C.,, M. S. Berninger, and, J. L. Hartley. 1990. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 93: 125– 128.
92.
Mahony, J.,, S. Chong,, F. Merante,, S. Yaghoubian,, T. Sinha,, C. Lisle, and, R. Janeczko. 2007. Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. J. Clin. Microbiol. 45: 2965– 2970.
93.
Mahony, J. B.,, and M. A. Chernesky. 1999. Immunoassays for the diagnosis of infectious diseases, p. 202–214. In P. R. Murray,, E. J. Baron,, M. A. Pfaller,, F. C. Tenover, and, R. H. Yolken (ed.), Manual of Clinical Microbiology, 7th ed. ASM Press, Washington, DC.
94.
Mandy, F. F.,, T. Nakamura,, M. Bergeron, and, K. Sekiguchi. 2001. Overview and application of suspension array technology. Clin. Lab. Med. 21: 713– 729.
95.
Marshall, J. A.,, and L. D. Bruggink. 2006. Laboratory diagnosis of norovirus. Clin. Lab. 52: 571– 581.
96.
Martin, M.,, C. Gilbert,, E. Covington, and, G. Boivin. 2006. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. J. Infect. Dis. 194: 579– 583.
97.
Martínez, P. M.,, A. R. Torres,, R. Ortiz de Lejarazu,, A. Montoya,, J. F. Martin, and, J. M. Eiros. 1999. Human immunodeficiency virus antibody testing by enzyme-linked fluorescent and Western blot assays using serum, gingival-crevicular transudate, and urine samples. J. Clin. Microbiol. 37: 1100– 1106.
98.
Martins, T. B. 2002. Development of internal controls for the Luminex instrument as part of a multiplex sevenanalyte viral respiratory antibody profile. Clin. Diagn. Lab. Immunol. 9: 41– 45.
99.
McKimm-Breschkin, J. L. 2000. Resistance of influenza viruses to neuraminidase inhibitors—a review. Antivir. Res. 47: 1– 17.
100.
McLaren, C.,, M. N. Ellis, and, G. A. Hunter. 1983. A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents. Antivir. Res. 3: 223– 234.
101.
McSharry, J. M.,, N. S. Lurain,, G. L. Drusano,, A. Landay,, J. Manischewitz,, M. Nokta,, M. O’Gorman,, H. M. Shapiro,, A. Weinberg,, P. Reichelderfer, and, C. Crumpacker. 1998. Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates. J. Clin. Microbiol. 36: 958– 964.
102.
Morris, T.,, B. Robertson, and, M. Gallagher. 1996. Rapid reverse transcription-PCR detection of hepatitis C virus RNA in serum by using the TaqMan fluorogenic detection system. J. Clin. Microbiol. 34: 2933– 2936.
103.
Mushahwar, I. K.,, and T. A. Brawner. 2000. Radio-immunoassay, p. 79–92. In S. C. Specter,, R. L. Hodinka, and, S. A. Young (ed.), Clinical Virology Manual, 3rd ed. ASM Press, Washington, DC.
104.
NCCLS. 2004. Antiviral susceptibility testing: herpes simplex virus by plaque reduction assay. Standard M33-A. NCCLS, Wayne, PA.
105.
Nichol, S. T.,, C. F. Spiropoulou,, S. Morzunov,, P. E. Rollin,, T. G. Ksiazek,, H. Feldmann,, A. Sanchez,, J. Childs,, S. Zaki, and, C. J. Peters. 1993. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 262: 914– 917.
106.
Oberste, M. S.,, K. Maher,, D. R. Kilpatrick,, M. R. Flemister,, B. A. Brown, and, M. A. Pallansch. 1999. Typing of human enteroviruses by partial sequencing of VP1. J. Clin. Microbiol. 37: 1288– 1293.
107.
Olivo, P. D. 1996. Transgenic cell lines for detection of animal viruses. Clin. Microbiol. Rev. 9: 321– 334.
108.
Opalka, D.,, C. E. Lachman,, S. A. MacMullen,, K. U. Jansen,, J. F. Smith,, N. Chirmule, and, M. T. Esser. 2003. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed Luminex assay. Clin. Diagn. Lab. Immunol. 10: 108– 115.
109.
Otsu, R.,, A. Ishikawa, and, K. Mukae. 2000. Detection of small round structured viruses in stool specimens from outbreaks of gastroenteritis by electron microscopy and reverse transcription-polymerase chain reaction. Acta Virol. 44: 53– 55.
110.
Parker, S. P.,, W. D. Cubitt, and, A. E. Ades. 1997. A method for the detection and confirmation of antibodies to hepatitis C virus in dried blood spots. J. Virol. Methods 68: 199– 205.
111.
Pasloske, B. L.,, C. R. Walkerpeach,, R. D. Obermoeller,, M. Winkler, and, D. B. DuBois. 1998. Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards. J. Clin. Microbiol. 36: 3590– 3594.
112.
Peterson, E.,, O. W. Schmidt,, L. C. Goldstein,, R. C. Nowinski, and, L. Corey. 1983. Typing of clinical herpes simplex virus isolates with mouse monoclonal antibodies to herpes simplex virus types 1 and 2: comparison with type-specific rabbit antisera and restriction endonuclease analysis of viral DNA. J. Clin. Microbiol. 17: 92– 96.
113.
Petropoulos, C. J.,, N. T. Parkin,, K. L. Limoli,, Y. S. Lie,, T. Wrin,, W. Huang,, H. Tian,, D. Smith,, G. A. Winslow,, D. J. Capon, and, J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44: 920– 928.
114.
Potier, M.,, L. Mameli,, M. Belisle,, L. Dallaire, and, S. B. Melancon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D- N- acetylneuraminate) substrate. Anal. Biochem. 94: 287– 296.
115.
Pugliese, A.,, T. Beltramo, and, D. Torre. 2007. Emerging and re-emerging viral infections in Europe. Cell Biochem. Funct. 25: 1– 13.
116.
Randhawa, P.,, A. Vats, and, R. Shapiro. 2005. Monitoring for polyomavirus BK and JC in urine: comparison of quantitative polymerase chain reaction with urine cytology. Transplantation 79: 984– 986.
117.
Rawlins, M. L.,, E. M. Swenson,, H. R. Hill, and, C. M. Litwin. 2007. Evaluation of an enzyme immunoassay for detection of immunoglobulin M antibodies to West Nile virus and the importance of background subtraction in detecting nonspecific reactivity. Clin. Vaccine Immunol. 14: 665– 668.
118.
Revets, H.,, D. Marissens,, S. de Wit,, P. Lacor,, N. Clumeck,, S. Lauwers, and, G. Zissis. 1996. Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICORHIV Monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 34: 1058– 1064.
119.
Rotbart, H. A. 1991. Nucleic acid detection systems for enteroviruses. Clin. Microbiol. Rev. 4: 156– 168.
120.
Saiki, R. K.,, S. Scharf,, F. Faloona,, K. B. Mullis,, G. T. Horn,, H. A. Erlich, and, N. Arnheim. 1992. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. 1985. Biotechnology 24: 476– 480.
121.
Sarantis, H.,, G. Johnson,, M. Brown,, M. Petric, and, R. Tellier. 2004. Comprehensive detection and serotyping of human adenoviruses by PCR and sequencing. J. Clin. Microbiol. 42: 3963– 3969.
122.
Sarkies, N.,, Z. Gregor,, T. Forsey, and, S. Darougar. 1986. Antibodies to herpes simplex virus type I in intraocular fluids of patients with acute retinal necrosis. Br. J. Ophthalmol. 70: 81– 84.
123.
Schmit, I.,, and G. Boivin. 1999. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. J. Infect. Dis. 180: 487– 490.
124.
Schutzbank, T. A.,, and R. McGuire. 2000. Immunofluorescence, p. 69–78. In S. C. Specter,, R. L. Hodinka, and, S. A. Young (ed.), Clinical Virology Manual, 3rd ed. ASM Press, Washington, DC.
125.
Shafer, R. W. 2002. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15: 247– 277.
126.
Small, L. N.,, J. Lau, and, D. R. Snydman. 2006. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin. Infect. Dis. 43: 869– 880.
127.
Stabell, E. C.,, and P. D. Olivo. 1992. Isolation of a cell line for rapid and sensitive histochemical assay for the detection of herpes simplex virus. J. Virol. Methods 38: 195– 204.
128.
Stark, L. M.,, and A. L. Lewis. 2000. Complement fixation test, p. 112–126. In S. C. Specter,, R. L. Hodinka, and, S. A. Young (ed.), Clinical Virology Manual, 3rd ed. ASM Press, Washington, DC.
129.
Storch, G. A. 2000. Diagnostic virology. Clin. Infect. Dis. 31: 739– 751.
130.
Storch, G. A. (ed.). 2000. Essentials of Diagnostic Virology. Churchill Livingstone, New York, NY.
131.
Suttorp-Schulten, M. S.,, M. J. Zaal,, L. Luyendijk,, P. J. Bos,, A. Kijlstra, and, A. Rothova. 1989. Aqueous chamber tap and serology in acute retinal necrosis. Am. J. Ophthalmol. 108: 327– 328.
132.
Tebas, P.,, E. C. Stabell, and, P. D. Olivo. 1995. Antiviral susceptibility testing with a cell line which expresses beta-galactosidase after infection with herpes simplex virus. Antimicrob. Agents Chemother. 39: 1287– 1291.
133.
Templeton, K. E.,, S. A. Scheltinga,, M. F. Beersma,, A. C. Kroes, and, E. C. Claas. 2004. Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by influenza A and influenza B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, 3, and 4. J. Clin. Microbiol. 42: 1564– 1569.
134.
Theilmann, L.,, M. Fischer,, P. R. Galle, and, M. Nassal. 1989. Detection of HBV DNA in HBsAg-positive sera after amplification using the polymerase chain reaction. Liver 9: 322– 328.
135.
Thomas, D. L.,, J. Astemborski,, R. M. Rai,, F. A. Anania,, M. Schaeffer,, N. Galai,, K. Nolt,, K. E. Nelson,, S. A. Strathdee,, L. Johnson,, O. Laeyendecker,, J. Boitnott,, L. E. Wilson, and, D. Vlahov. 2000. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284: 450– 456.
136.
Tsongalis, G. J.,, T. Gleeson,, M. Rodina,, D. Anamani,, J. Ross,, I. Joanisse,, L. Tanimoto, and, R. Ziermann. 2005. Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates. J. Clin. Virol. 34: 268– 271.
137.
Urdea, M. S. 1993. Synthesis and characterization of branched DNA (bDNA) for the direct and quantitative detection of CMV, HBV, HCV, and HIV. Clin. Chem. 39: 725– 726.
138.
van den Hoogen, B. G.,, J. C. de Jong,, J. Groen,, T. Kuiken,, R. de Groot,, R. A. Fouchier, and, A. D. Osterhaus. 2001. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med. 7: 719– 724.
139.
von Lode, P. 2005. Point-of-care immunotesting: approaching the analytical performance of central laboratory methods. Clin. Biochem. 38: 591– 606.
140.
Walker, G. T.,, J. G. Nadeau,, P. A. Spears,, J. L. Schram,, C. M. Nycz, and, D. D. Shank. 1994. Multiplex strand displacement amplification (SDA) and detection of DNA sequences from Mycobacterium tuberculosis and other mycobacteria. Nucleic Acids Res. 22: 2670– 2677.
141.
Wang, D.,, L. Coscoy,, M. Zylberberg,, P. C. Avila,, H. A. Boushey,, D. Ganem, and, J. L. DeRisi. 2002. Microarray-based detection and genotyping of viral pathogens. Proc. Natl. Acad. Sci. USA 99: 15687– 15692.
142.
Wang, D.,, A. Urisman,, Y. T. Liu,, M. Springer,, T. G. Ksiazek,, D. D. Erdman,, E. R. Mardis,, M. Hickenbotham,, V. Magrini,, J. Eldred,, J. P. Latreille,, R. K. Wilson,, D. Ganem, and, J. L. DeRisi. 2003. Viral discovery and sequence recovery using DNA microarrays. PLoS Biol. 1: E2.
143.
Warford, A. 2000. Quality assurance in clinical virology, p. 3–10. In S. C. Specter,, R. L. Hodinka, and, S. A. Young (ed.), Clinical Virology Manual, 3rd ed. ASM Press, Washington, DC.
144.
Wiedbrauk, D. L. 2000. Nucleic acid amplification methods, p. 188–197. In S. C. Specter,, R. L. Hodinka, and, S. A. Young (ed.), Clinical Virology Manual, 3rd ed. ASM Press, Washington, DC.
145.
Wiedbrauk, D. L.,, and H. Y. K. Chuang. 1988. Managing IgM serologies: getting the IgG out. Lab. Manag. 26: 24– 27.
146.
Wiedmann, M.,, W. J. Wilson,, J. Czajka,, J. Luo,, F. Barany, and, C. A. Batt. 1994. Ligase chain reaction (LCR)—overview and applications. PCR Methods Appl. 3: S51– S64.
147.
Wittek, M.,, M. Sturmer,, H. W. Doerr, and, A. Berger. 2007. Molecular assays for monitoring HIV infection and antiretroviral therapy. Expert Rev. Mol. Diagn. 7: 237– 246.
148.
Wittwer, C. T.,, M. G. Herrmann,, A. A. Moss, and, R. P. Rasmussen. 1997. Continuous fluorescence monitoring of rapid cycle DNA amplification. BioTechniques 22: 130– 131, 134–138.
149.
Wong, S. J.,, R. H. Boyle,, V. L. Demarest,, A. N. Woodmansee,, L. D. Kramer,, H. Li,, M. Drebot,, R. A. Koski,, E. Fikrig,, D. A. Martin, and, P. Y. Shi. 2003. Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. J. Clin. Microbiol. 41: 4217– 4223.
150.
Yamaguchi, K.,, Y. Yonemura,, H. Okabe,, Y. Takahama,, S. Nagai,, H. Yamaguchi, and, K. Hirai. 2003. Detection of anti-human T-lymphotropic virus type I antibody in whole blood by a novel counting immunoassay. Clin. Chem. 49: 275– 280.
151.
Young, S. A.,, and L. C. McLaren. 2000. Hemagglutination inhibition and hemadsorption, p. 135–139. In S. C. Specter,, R. L. Hodinka, and, S. A. Young (ed.), Clinical Virology Manual, 3rd ed. ASM Press, Washington, DC.
152.
Zolopa, A. R. 2006. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection. J. Infect. Dis. 194 (Suppl. 1) : S59– S64.
Tables
Diagnosis of Viral Infections*
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815981.ch13-1,webId=/content/author/10.1128/9781555815981.ch13-1,properties={foaf_givenname=Guy, foaf_name=Guy Boivin, foaf_surname=Boivin}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815981.ch13-2,webId=/content/author/10.1128/9781555815981.ch13-2,properties={foaf_givenname=Tony, foaf_name=Tony Mazzulli, foaf_surname=Mazzulli}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815981.ch13-3,webId=/content/author/10.1128/9781555815981.ch13-3,properties={foaf_givenname=Martin, foaf_name=Martin Petric, foaf_surname=Petric}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815981.ch13-4,webId=/content/author/10.1128/9781555815981.ch13-4,properties={foaf_givenname=Michel, foaf_name=Michel Couillard, foaf_surname=Couillard}]]
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13tab01
TABLE 1
Susceptibility of cell culture types to commonly isolated human viruses
a
TABLE 1
Susceptibility of cell culture types to commonly isolated human viruses a
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13tab02
TABLE 2
Times required to detect viruses in cell culture
a
TABLE 2
Times required to detect viruses in cell culture a
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13tab03
TABLE 3
IC50 cutoffs for HSV and CMV antiviral resistance using PRA
TABLE 3
IC50 cutoffs for HSV and CMV antiviral resistance using PRA
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13tab04
TABLE 4
Cytological changes associated with selected viral infections
TABLE 4
Cytological changes associated with selected viral infections
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13tab05
TABLE 5
Detection of viral antigens by DFA staining
TABLE 5
Detection of viral antigens by DFA staining
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13tab06
TABLE 6
Utility of serologic determinations in clinical virology
TABLE 6
Utility of serologic determinations in clinical virology
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13tab07
TABLE 7
Examples of viruses for which IgM serologic determinations are useful and commercial reagents and/or kits are available
TABLE 7
Examples of viruses for which IgM serologic determinations are useful and commercial reagents and/or kits are available
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13
/content/10.1128/9781555815981.ch13.ch13tab08
TABLE 8
Interpretation of results for virus-specific antibodies in clinical virology
TABLE 8
Interpretation of results for virus-specific antibodies in clinical virology
Citation:
Boivin G, Mazzulli T, Petric M, Couillard M.
2009.
Diagnosis of Viral Infections*,
p 265-294.
In
Richman D, Whitley R, Hayden F (ed),
Clinical Virology, Third Edition.
ASM Press, Washington, DC.
doi: 10.1128/9781555815981.ch13